Annovis Bio starts Phase 3 Alzheimer's trial, reports Q1 net loss $0.32 per share, cash $22.2M

Annovis Bio, Inc.

2025-Q1 EPS reported -$0.32

First participants entered pivotal Phase 3 AD trial on Feb 5, 2025; planning 760 participants, evaluating buntanetap.
Cash and equivalents $22.2M as of Mar 31, 2025 (vs $10.6M a year ago).
R&D expenses $5.0M in Q1 2025 vs $6.5M Q1 2024; G&A flat at $1.3M.
Net loss per share $0.32 basic/diluted for Q1 2025 vs $0.10 basic and $0.72 diluted in Q1 2024.
Appointed Andrew Walsh (VP Finance) as Principal Financial Officer; salary $264,000 + 25% target bonus.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Walsh

Principal Financial Officer

ANVS · Annovis Bio, Inc.

Effective: 2025-05-09
Filed: May 13, 2025, 7:59 PM ET

On May 9, 2025, the Board of Directors appointed Andrew Walsh, the Company’s current Vice President of Finance, as the Company’s Principal Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Walsh was appointed as Principal Financial Officer at Annovis Bio, Inc..

Action: appointed
Role: Principal Financial Officer

Exact text from the filing

On May 9, 2025, the Board of Directors appointed Andrew Walsh, the Company’s current Vice President of Finance, as the Company’s Principal Financial Officer.

View on SEC.gov

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-047871

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.